Fast Five Quiz: Non-Hodgkin's Lymphoma: Mantle Cell Lymphoma Practice Essentials

Ann S. LaCasce, MD, MMSc


May 22, 2023

According to the NCCN guidelines, chemoimmunotherapy is a recommended option for patients without a TP53 mutation who are not candidates for ASCT. Clinical trials are preferred where possible for those harboring a TP53 mutation. ASCT has not been shown to be beneficial in these patients, and chemoimmunotherapy, while an option, is suboptimal.

Currently, CAR T therapy is typically an option in the third-line setting after chemoimmunotherapy and Bruton's tyrosine kinase inhibitor therapy for fit patients, per the same guidelines. However, the treatment landscape is rapidly evolving, and earlier use of CAR T has been suggested for certain patients. In a recent literature review conducted by M. Al-Mansour, a treatment algorithm was proposed that included CAR T therapy as a second-line option for unfit patients. Additionally, international practice guidelines suggest that CAR T may also be considered for patients with TP53 mutation second line.

Radiation therapy may be an option in patients with early-stage disease or in the palliative care setting.

Learn more about MCL.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.